Clinical Trials Logo

IBD - Inflammatory Bowel Disease clinical trials

View clinical trials related to IBD - Inflammatory Bowel Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT04143633 Recruiting - Clinical trials for IBS - Irritable Bowel Syndrome

Low FODMAP Diet on Nutritional Status, Disease Activity and Gut Microbiota in IBS and UC With Normal or Overweight BMI

Start date: February 10, 2018
Phase: N/A
Study type: Interventional

Gastrointestinal disorders represents 20-50% of referrals to the gastroenterologist; being the most affected womens, youths and older adults. Among these alterations are the Irritable Bowel Syndrome (IBS) and Ulcerative Colitis (UC), which affects the gut causing impaired motility. The pharmacological and nutritional treatment are modified according to the symptomatology and activity of each patients. Currently the implementation of low FODMAP diets for 6 to 8 weeks in patients whith IBS improves symptoms such as bloating, flatulence and abdominal pain. However due to the number of restricted foods a long term attachment could limited the nutritional content, consequently affecting the nutritional status, gut microbiota an quality of life. A low FODMAP diet are useful to improve gastrointestinal symptoms in patients with UC and causes changes in nutritional status.

NCT ID: NCT01896986 Active, not recruiting - Clinical trials for PRD (Paediatric Rheumatological Disease)

HPV Vaccination in Special Risk Groups: 5 Year Follow-up

Start date: March 2012
Phase: N/A
Study type: Observational

In 2007-2009 the investigators conducted a study to determine the immunogenicity response to HPV vaccine in special risk patients known to be at increased risk of abnormal cervical cytology. The serological response to the vaccine was measured 1 month post the third and final dose (n=70) finding a robust response overall. The aim of this follow-on study is to provide data on the long-term protection offered by the HPV vaccination. The persistence of antibody 5 years post immunisation is unknown and the impact on cervical cytology abnormalities in these special risk groups is important. The study results will help inform national immunisation program recommendations re- booster HPV vaccine doses.